Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today commented on the recently released Centers for Medicare and Medicaid Services (CMS) Calen...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment and randomization in its U.S. Food and Dru...
Glaukos (GKOS) announces that the Therapeutic Goods Administration ((TGA)) of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure ((IOP)) in eyes of certain patients with primary open-angle glaucoma.The approval a...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the Therapeutic Goods Administration (TGA) of Australia has granted regula...
I covered Glaukos twice last year during what I felt like was a temporary setback due to the COVID-19 pandemic. Since that time, Glaukos shares have rallied substantially as those headwinds started to subside. In this article, I update my thesis on what I still view to be a qualit...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair ...
Glaukos (GKOS) has entered into a new development and commercialization license agreement with Santen Pharmaceutical (SNPHF) for the Preserflo MicroShunt (DE-128), superseding the previous agreements between the two parties. Under the new agreement, Glaukos obtains exclusive commercialization...
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreem...
IRIX recently blew away analyst estimates for Q1 sales, with multiple tailwinds for continued success in 2021 and beyond. The company’s recent partnership with Japanese giant, Topcon, validates IRIX’s technology and takes the threat of a dilutive capital raise off the ta...
Image source: The Motley Fool. Glaukos Corp (NYSE: GKOS) Q1 2021 Earnings Call May 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Glaukos Corp (GKOS) Q1 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...